O.I.

OncoImmunin, Inc. (OI) is a biotechnology company specializing in the development of cell-permeable fluorogenic substrates for measuring protease activities in live cells. Founded in 1996 and based in Gaithersburg, Maryland, the company is widely recognized for its proprietary technology involving intramolecular excitonic dimers, which enables the detection of programmed cell death and immune effector functions through products like PhiPhiLux and GranToxiLux. Beyond its established assay business, OncoImmunin is leveraging its patented delivery platform to develop therapeutic applications in RNA interference and immunotherapy. The company's research pipeline includes programs targeting PD-1 for cancer immunotherapy and the knockdown of HIV genes for antiviral therapy.